Wilms tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene

Blood

Volumn 107, Issue 11, 2006, Pages 4282-4290

  Dame, Christof ^a   Kirschner, Karin M ^b   Bartz, Katharina V ^b   Wallach, Thomas ^b   Hussels, Christiane S ^b   Scholz, Holger ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; MESSENGER RNA; WT1 PROTEIN;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE DELETION; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HOMOZYGOSITY; HUMAN; HUMAN CELL; LIVER CELL; MALE; MOUSE; NEPHROBLASTOMA; NERVE CELL; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; SERTOLI CELL; SPINAL GANGLION; TESTIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 33744472466     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-2889     Document Type: Article

References (59)

1. Peschle C, Marone G, Genovese A, Cillo C, Magli C, Condorelli M. Erythropoietin production by the liver in fetal-neonatal life. Life Sci. 1975;17:1325-1330.
2. Zanjani ED, Poster J, Burlington H, Mann LI, Wasserman LR. Liver as the primary site of erythropoietin formation in the fetus. J Lab Clin Med. 1977;89:640-644.
3. Dame C, Fahnenstich H, Freitag P, et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood. 1998;92:3218-3225.
4. Masuda S, Nagao M, Sasaki R. Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol. 1999;70:1-6.
5. Gassmann M, Heinicke K, Soliz J, et al. Non-erythroid functions of erythropoietin. Adv Exp Med Biol. 2003;543:323-330.
6. Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol. 2004;83:673-686.
7. Tan CC, Eckardt KU, Firth JD, Ratcliffe PJ. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol. 1992;263:F474-F481.
8. Chikuma M, Masuda S, Kobayashi T, Nagao M, Sasaki R. Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am J Physiol Endocrinol Metab. 2000;279:E1242-E1248.
9. Dame C, Sola MC, Lim KC, et al. Hepatic erythropoietin gene regulation by GATA-4. J Biol Chem. 2004;279:2955-2961.
10. Fandrey J. Oxygen-dependent and tissuespecific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol. 2004;286:R977-R988.
11. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood. 1999;94:1864-1877.
12. Blanchard KL, Acquaviva AM, Galson DL, Bunn HF. Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol. 1992;12:5373-5385.
13. Gupta M, Goldwasser E. The role of the near upstream sequence in hypoxia-induced expression of the erythropoietin gene. Nucleic Acids Res. 1996;24:4768-4774.
14. Gupta M, Mungai PT, Goldwasser E. A new transacting factor that modulates hypoxia-induced expression of the erythropoietin gene. Blood. 2000;96:491-497.
15. Sanchez-Elsner T, Ramirez JR, Sanz-Rodriguez F, et al. A cross-talk between hypoxia and TGFbeta orchestrates erythropoietin gene regulation through SP1 and Smads. J Mol Biol. 2004;336:9-24.
16. Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood. 1997;89:1430-1439.
17. Alberta JA, Springett GM, Rayburn H, et al. Role of the WT1 tumor suppressor in murine hematopoiesis. Blood. 2003;101:2570-2574.
18. King-Underwood L, Little S, Baker M, et al. Wt1 is not essential for hematopoiesis in the mouse. Leuk Res. 2005;29:803-812.
19. Fraizer GC, Patmasiriwat P, Zhang X, Saunders GF. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow. Blood. 1995;86:4704-4706.
20. Moore AW, Schedl A, McInnes L, Doyle M, Hecksher-Sorensen J, Hastie ND. YAC transgenic analysis reveals Wilms' tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb. Mech Dev. 1998;79:169-184.
21. Kreidberg JA, Sariola H, Loring JM, et al. WT-1 is required for early kidney development. Cell. 1993;74:679-691.
22. Hammes A, Guo JK, Lutsch G, et al. Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell. 2001;106:319-329.
23. Moore AW, McInnes L, Kreidberg J, Hastie ND, Schedl A. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. Development. 1999;126:1845-1857.
24. Herzer U, Crocoll A, Barton D, Howells N, Englert C. The Wilms tumor suppressor gene wt1 is required for development of the spleen. Curr Biol. 1999;9:837-840.
25. Wagner KD, Wagner N, Vidal VP, et al. The Wilms' tumor gene Wt1 is required for normal development of the retina. EMBO J. 2002;21:1398-1405.
26. Wagner N, Wagner KD, Hammes A, et al. A splice variant of the Wilms' tumour suppressor Wt1 is required for normal development of the olfactory system. Development. 2005;132:1327-1336.
27. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res. 2001;264:74-99.
28. Wagner KD, Wagner N, Schley G, Theres H, Scholz H. The Wilms' tumor suppressor Wt1 encodes a transcriptional activator of the class IV POU-domain factor Pou4f2 (Brn-3b). Gene. 2003;305:217-223.
29. Sapetschnig A, Koch F, Rischitor G, Mennenga T, Suske G. Complexity of translationally controlled transcription factor Sp3 isoform expression. J Biol Chem. 2004;279:42095-42105.
30. Wagner KD, Wagner N, Sukhatme VP, Scholz H. Activation of vitamin D receptor by the Wilms' tumor gene product mediates apoptosis of renal cells. J Am Soc Nephrol. 2001;12:1188-1196.
31. Haber DA, Park S, Maheswaran S, et al. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science. 1993;262:2057-2059.
32. Dennig J, Beato M, Suske G. An inhibitor domain in Sp3 regulates its glutamine-rich activation domains. EMBO J. 1996;15:5659-5667.
33. Wagner KD, Wagner N, Wellmann S, et al. Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). FASEB J. 2003;17:1364-1366.
34. Larsson SH, Charlieu JP, Miyagawa K, et al. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell. 1995;81:391-401.
35. Englert C, Vidal M, Maheswaran S, et al. Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc Natl Acad Sci U S A. 1995;92:11960-11964.
36. Goldberg MA, Glass GA, Cunningham JM, Bunn HF. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci U S A. 1987;84:7972-7976.
37. Suske G. Transient transfection of Schneider cells in the study of transcription factors. Methods Mol Biol. 2000;130:175-187.
38. Koury MJ, Bondurant MC, Graber SE, Sawyer ST. Erythropoietin messenger RNA levels in developing mice and transfer of 125I-erythropoietin by the placenta. J Clin Invest. 1988;82:154-159.
39. Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND, Bard JB. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech Dev. 1993;40:85-97.
40. Rackley RR, Flenniken AM, Kuriyan NP, Kessler PM, Stoler MH, Williams BR. Expression of the Wilms' tumor suppressor gene WT1 during mouse embryogenesis. Cell Growth Differ. 1993;4:1023-1031.
41. Campana WM, Myers RR. Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury. FASEB J. 2001;15:1804-1806.
42. Sharma PM, Yang X, Bowman M, Roberts V, Sukumar S. Molecular cloning of rat Wilms' tumor complementary DNA and a study of messenger RNA expression in the urogenital system and the brain. Cancer Res. 1992;52:6407-6412.
43. Magnanti M, Gandini O, Giuliani L, et al. Erythropoietin expression in primary rat Sertoli and peritubular myoid cells. Blood. 2001;98:2872-2874.
44. Mioni R, Gottardello F, Bordon P, Montini G, Foresta C. Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells. Acta Endocrinol (Copenh). 1992;127:459-465.
45. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood. 1988;71:524-527.
46. Liapis H, Roby J, Birkland TP, Davila RM, Ritter D, Parks WC. In situ hybridization of human erythropoietin in pre- and postnatal kidneys. Pediatr Pathol Lab Med. 1995;15:875-883.
47. Lacombe C, Da Silva JL, Bruneval P, et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest. 1988;81:620-623.
48. Wagner N, Wagner KD, Xing Y, Scholz H, Schedl A. The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1. J Am Soc Nephrol. 2004;15:3044-3051.
49. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol. 1997;25:945-950.
50. Svedberg H, Richter J, Gullberg U. Forced expression of the Wilms tumor 1 (WT1) gene inhibits proliferation of human hematopoietic CD34(+) progenitor cells. Leukemia. 2001;15:1914-1922.
51. Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87:2878-2884.
52. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development. 1999;126:3597-3605.
53. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature. 1990;346:194-197.
54. Lovell MA, Xie C, Xiong S, Markesbery WR. Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. Brain Res. 2003;983:84-96.
55. Keswani SC, Leitz GJ, Hoke A. Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci Lett. 2004;371:102-105.
56. Yu X, Shacka JJ, Eells JB, et al. Erythropoietin receptor signalling is required for normal brain development. Development. 2002;129:505-516.
57. Natoli TA, Alberta JA, Bortvin A, et al. Wt1 functions in the development of germ cells in addition to somatic cell lineages of the testis. Dev Biol. 2004;268:429-440.
58. Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman D. Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev. 1991;5:1345-1356.
59. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985;82:7580-7584.